1-7 of 7
Phonphimon Wongthida
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 3503: XMT-2056, a HER2-targeted Immunosynthen STING-agonist antibody-drug conjugate, binds a novel epitope of HER2 and shows increased anti-tumor activity in combination with trastuzumab and pertuzumab

Free
Jeremy R. Duvall, Raghida A. Bukhalid, Naniye M. Cetinbas, Kalli C. Catcott, Kelly Lancaster, Keith W. Bentley, Suzanna Clark, Susan Clardy, Scott D. Collins, Anouk Dirksen, Elizabeth Ditty, Bingfan Du, Eugene W. Kelleher, Travis Monnell, Marina Protopopova, Caitlin Routhier, Cheri Stevenson, Elena Ter-Ovanesyan, Joshua D. Thomas, Alex Uttard, Jason Wang, Phonphimon Wongthida, Ling Xu, Annika Yau, Jeffrey Zurita, Dorin Toader, Marc Damelin, Timothy B. Lowinger
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 3503.
https://doi.org/10.1158/1538-7445.AM2022-3503
Published: 15 June 2022
View articletitled, Abstract 3503: XMT-2056, a HER2-targeted Immunosynthen STING-agonist antibody-drug conjugate, binds a novel epitope of HER2 and shows increased anti-tumor activity in combination with trastuzumab and pertuzumab
Journal Articles

Abstract 907: XMT-1660, a B7-H4-targeted Dolasynthen antibody-drug conjugate for the treatment of breast cancer

Free
Shawn P. Fessler, Jason Wang, Scott D. Collins, LiuLiang Qin, Kenneth Avocetien, Ling Xu, Ronald Eydelloth, Steven Vonderfecht, Chen-Ni Chin, Steven Bradley, Susan Clardy, Anouk Dirksen, Elizabeth Ditty, Bingfan Du, Dokyong Kim, Rebecca Mosher, Elena Ter-Ovanesyen, Kelly Slocum, Alex Uttard, Phonphimon Wongthida, Jeffrey Zurita, Dorin Toader, Marc Damelin, Timothy B. Lowinger
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 907.
https://doi.org/10.1158/1538-7445.AM2021-907
Published: 01 July 2021
View articletitled, Abstract 907: XMT-1660, a B7-H4-targeted Dolasynthen antibody-drug conjugate for the treatment of breast cancer
Journal Articles

Abstract 1738: XMT-2056, a well-tolerated, Immunosynthen-based STING-agonist antibody-drug conjugate which induces anti-tumor immune activity

Free
Jeremy R. Duvall, Raghida A. Bukhalid, Naniye M. Cetinbas, Kalli C. Catcott, Kelly Slocum, Kenneth Avocetien, Keith W. Bentley, Stephen Bradley, Susan Clardy, Scott D. Collins, Elizabeth Ditty, Timothy Eitas, Brian D. Jones, Eugene W. Kelleher, Winnie Lee, Travis Monnell, Rebecca Mosher, Marina Protopopova, LiuLiang Qin, Pamela Shaw, Elena Ter-Ovanesyan, Joshua D. Thomas, Phonphimon Wongthida, Ling Xu, Liping Yang, Jeffrey Zurita, Dorin Toader, Marc Damelin, Timothy B. Lowinger
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 1738.
https://doi.org/10.1158/1538-7445.AM2021-1738
Published: 01 July 2021
View articletitled, Abstract 1738: XMT-2056, a well-tolerated, Immunosynthen-based STING-agonist antibody-drug conjugate which induces anti-tumor immune activity
Journal Articles

Systemic Combination Virotherapy for Melanoma with Tumor Antigen-Expressing Vesicular Stomatitis Virus and Adoptive T-cell Transfer

Free
Diana M. Rommelfanger, Phonphimon Wongthida, Rosa M. Diaz, Karen M. Kaluza, Jill M. Thompson, Timothy J. Kottke, Richard G. Vile
Journal: Cancer Research
Cancer Res (2012) 72 (18): 4753–4764.
https://doi.org/10.1158/0008-5472.CAN-12-0600
Published: 16 September 2012
View articletitled, Systemic Combination Virotherapy for Melanoma with Tumor Antigen-Expressing Vesicular Stomatitis Virus and Adoptive T-cell Transfer
Open the PDF for Systemic Combination Virotherapy for Melanoma with Tumor Antigen-Expressing Vesicular Stomatitis Virus and Adoptive T-cell Transfer in another window
Includes: Supplementary data
Journal Articles

Type III IFN Interleukin-28 Mediates the Antitumor Efficacy of Oncolytic Virus VSV in Immune-Competent Mouse Models of Cancer

Free
Phonphimon Wongthida, Rosa Maria Diaz, Feorillo Galivo, Timothy Kottke, Jill Thompson, Jose Pulido, Kevin Pavelko, Larry Pease, Alan Melcher, Richard Vile
Journal: Cancer Research
Cancer Res (2010) 70 (11): 4539–4549.
https://doi.org/10.1158/0008-5472.CAN-09-4658
Published: 01 June 2010
View articletitled, Type III IFN Interleukin-28 Mediates the Antitumor Efficacy of Oncolytic Virus VSV in Immune-Competent Mouse Models of Cancer
Open the PDF for Type III IFN Interleukin-28 Mediates the Antitumor Efficacy of Oncolytic Virus VSV in Immune-Competent Mouse Models of Cancer in another window
Journal Articles

Expression of IFN-β Enhances Both Efficacy and Safety of Oncolytic Vesicular Stomatitis Virus for Therapy of Mesothelioma

Free
Candice L. Willmon, Vassiliki Saloura, Zvi G. Fridlender, Phonphimon Wongthida, Rosa Maria Diaz, Jill Thompson, Timothy Kottke, Mark Federspiel, Glen Barber, Steven M. Albelda, Richard G. Vile
Journal: Cancer Research
Cancer Res (2009) 69 (19): 7713–7720.
https://doi.org/10.1158/0008-5472.CAN-09-1013
Published: 01 October 2009
View articletitled, Expression of IFN-β Enhances Both Efficacy and Safety of Oncolytic Vesicular Stomatitis Virus for Therapy of Mesothelioma
Open the PDF for Expression of IFN-β Enhances Both Efficacy and Safety of Oncolytic Vesicular Stomatitis Virus for Therapy of Mesothelioma in another window
Journal Articles

Oncolytic Immunovirotherapy for Melanoma Using Vesicular Stomatitis Virus

Free
Rosa Maria Diaz, Feorillo Galivo, Timothy Kottke, Phonphimon Wongthida, Jian Qiao, Jill Thompson, Mikael Valdes, Glen Barber, Richard G. Vile
Journal: Cancer Research
Cancer Res (2007) 67 (6): 2840–2848.
https://doi.org/10.1158/0008-5472.CAN-06-3974
Published: 15 March 2007
View articletitled, Oncolytic Immunovirotherapy for Melanoma Using Vesicular Stomatitis Virus
Open the PDF for Oncolytic Immunovirotherapy for Melanoma Using Vesicular Stomatitis Virus in another window